Localized Brain Stimulation with Mild Magnetic Hyperthermia Promotes Microglia Activity Towards Reactive and Autophagic Phenotypes in Vivo
SHANGHAI, CHINA, JUL 10 – Microglia replacement therapy by Bo Peng halts ALSP progression and stabilizes cognitive and motor functions for at least 24 months in patients, researchers report.
9 Articles
9 Articles


‘We finally have a name’: At long last, Manhattan family gets an answer to daughter's rare genetic condition
As with so many calls previously about 9-year-old Delilah, Kelli Stanley braced for more uncertainty. But this time was different. This time, they finally had a name.
Localized brain stimulation with mild magnetic hyperthermia promotes microglia activity towards reactive and autophagic phenotypes in vivo
The principle of magnetic hyperthermia is to generate localized heating on target proteins, cells and tissue that are targeted by magnetic nanoparticles (MNPs) upon stimulation by remotely applied high frequency alternating magnetic field (AMF). Beyond its traditional applications in hyperthermia therapy, recent studies demonstrated the feasibility of magnetic hyperthermia as a new strategy for neural stimulation. The objective of this study is …


Fatal genetic disorder treated by replacing the brain's immune cells
Microglia replacement therapy helps treat people with a rare genetic condition called ALSP, suggesting the approach could also work for other neurological disorders like Alzheimer’s
Microglia replacement halts progression of rare genetic brain disease in mice and humans
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a progressive neurological disease with an average age of onset at 43 years and an average life expectancy of only three to five years after symptoms begin. ALSP is caused by microglial mutations in the immune cells of the central nervous system (CNS). Currently, ALSP has no cure and treatments are limited.
Microglia Replacement Halts Progression of Fatal Neurological Disease in Mice and Humans
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a progressive neurological disease with an average age of onset of 43 years and an average life expectancy of only 3 to 5 years after symptoms begin.
Rare Brain Disease ALSP Stalled by Microglia Replacement via Bone Marrow
It’s hard to overstate how crucial microglia are to brain health. These humble immune cells quietly patrol the central nervous system, clearing debris, pruning synapses, and maintaining myelin. But when microglia malfunction, their dysfunction ripples through the brain. A striking example is adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease driven by microglial gene mutati…
Coverage Details
Bias Distribution
- 80% of the sources are Center
To view factuality data please Upgrade to Premium